Predictive Oncology Inc
POAI
查看詳細走勢圖
5.950USD
0.000
收盤 12/24, 13:00（美東）報價延遲15分鐘
4.56M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
0.00%
5天
0.00%
1月
-4.80%
6月
-54.92%
今年開始到現在
-51.63%
1年
-46.83%
查看詳細走勢圖
TradingKey Predictive Oncology Inc股票評分
單位: USD 更新時間: 2025-12-11操作建議
Predictive Oncology Inc當前公司基本面數據相對謹慎，增長潛力較大。當前估值合理，在生物技術與醫療研究行業排名229/405位。機構持股佔比低，近一個月多位分析師給出公司評級為。最高目標價3.00。中期看，股價處於下降通道。近一個月，市場表現較差，但技術面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Predictive Oncology Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
0
分析師
--
評級
3.000
目標均價
+251.62%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Predictive Oncology Inc亮點
亮點風險
Predictive Oncology Inc. is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
業績增長期
公司處於發展階段，最新年度總收入1.62M美元
估值高估
公司最新PE估值-0.04，處於3年歷史高位
機構減倉
最新機構持股7.39K股，環比減少77.87%
先鋒集團持倉
明星投資者先鋒集團持倉，最新持倉0.00股
Predictive Oncology Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Predictive Oncology Inc簡介
Predictive Oncology Inc. is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
公司代碼POAI
公司Predictive Oncology Inc
CEOVennare (Raymond F)
網址https://predictive-oncology.com/
常見問題
Predictive Oncology Inc(POAI)的當前股價是多少？
Predictive Oncology Inc(POAI)的當前股價是 5.950。
Predictive Oncology Inc 的股票代碼是什麼？
Predictive Oncology Inc的股票代碼是POAI。
Predictive Oncology Inc股票的52週最高點是多少？
Predictive Oncology Inc股票的52週最高點是45.900。
Predictive Oncology Inc股票的52週最低點是多少？
Predictive Oncology Inc股票的52週最低點是3.880。
Predictive Oncology Inc的市值是多少？
Predictive Oncology Inc的市值是4.56M。
Predictive Oncology Inc的淨利潤是多少？
Predictive Oncology Inc的淨利潤為-12.66M。
現在Predictive Oncology Inc(POAI)的股票是買入、持有還是賣出？
根據分析師評級，Predictive Oncology Inc(POAI)的總體評級為--，目標價格為3.000。
Predictive Oncology Inc(POAI)股票的每股收益（EPS TTM）是多少
Predictive Oncology Inc(POAI)股票的每股收益（EPS TTM）是-139.762。
相關品種
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
